How Effective is Vaccination in Preventing Pneumococcal Disease?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 229-241

  Musher, Daniel M ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Community acquired pneumonia; Pneumococcus; Pneumonia; Streptococcus pneumoniae; Vaccine

Indexed keywords

BACTERIAL VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; PNU IMMUNE 23; PROTEIN CONJUGATE POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

CROSS PRESENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HISTORY; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOSTIMULATION; INFECTION PREVENTION; NONHUMAN; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVACCINATION; REVIEW; SEROTYPE; SINGLE DRUG DOSE; VACCINATION;

HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 84873549672     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.011     Document Type: Review

References (52)

1. Musher D.M., Watson D.A., Dominguez E.A. Pneumococcal vaccination: work to date and future prospects. Am J Med Sci 1990, 300(1):45-52.
2. Heffron R. Pneumonia with special reference to pneumococcus lobar pneumonia 1939, The Commonwealth Fund, New York.
3. Orenstein A.J. Vaccine prophylaxis in pneumonia: a review of fourteen years' experience with inoculation of native mine workers on the Witwatersrand against pneumonia. J Med Assoc South Africa 1931, 5:339-346.
4. Smillie W.G., Wornock G.H., White H.J. A study of a type I pneumococcus epidemic at the State Hospital at Worcester, Mass. Am J Public Health Nations Health 1938, 28:293-302.
5. MacLeod C.M., Hodges R.G., Heidelberger M., et al. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945, 82:445-465.
6. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964, 60:759-776.
7. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981, 3(Suppl):S1-S17.
8. Moberley S.A., Holden J., Tatham D.P., et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, (1). CD000422.
9. Huss A., Scott P., Stuck A.E., et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58.
10. Musher D.M. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?. Clin Infect Dis 2012, 55(2):265-267.
11. Maruyama T., Taguchi O., Niederman M.S., et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010, 340:c1004.
12. Hechter R.C., Chao C., Jacobsen S.J., et al. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study. Vaccine 2012, 30(38):5625-5630.
13. Johnstone J., Eurich D.T., Minhas J.K., et al. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010, 51(1):15-22.
14. Johnstone J., Marrie T.J., Eurich D.T., et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007, 167(18):1938-1943.
15. Fisman D.N., Abrutyn E., Spaude K.A., et al. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006, 42(8):1093-1101.
16. Bolan G., Broome C.V., Facklam R.R., et al. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986, 104(1):1-6.
17. Sims R.V., Steinmann W.C., McConville J.H., et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988, 108(5):653-657.
18. Shapiro E.D., Berg A.T., Austrian R., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325(21):1453-1460.
19. Farr B.M., Johnston B.L., Cobb D.K., et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995, 155(21):2336-2340.
20. Jackson L.A., Neuzil K.M., Yu O., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348(18):1747-1755.
21. Musher D.M., Rueda-Jaimes A.M., Graviss E.A., et al. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 2006, 43(8):1004-1008.
22. Dominguez A., Izquierdo C., Salleras L., et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010, 36(3):608-614.
23. Blumberg E.A., Brozena S.C., Stutman P., et al. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001, 32(2):307-310.
24. Ridda I., Macintyre C.R., Lindley R., et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009, 27(10):1628-1636.
25. Musher D.M., Rueda A.M., Nahm M.H., et al. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008, 198(7):1019-1027.
26. Romero-Steiner S., Musher D.M., Cetron M.S., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999, 29(2):281-288.
27. Rodriguez-Barradas M.C., Musher D.M., Lahart C., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992, 165(3):553-556.
28. Rodriguez-Barradas M.C., Alexandraki I., Nazir T., et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003, 37(3):438-447.
29. Centers for Disease Control and Prevention Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010, 59(34):1102-1106.
30. Musher D.M., Manoff S.B., Liss C., et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010, 201:515-524.
31. Musher D.M., Manoff S.B., McFetridge R.D., et al. Pneumococcal polysaccharide vaccine, and immunogenicity and safety of 2nd and 3d doses in older adults. Hum Vaccin 2011, 7:919-928.
32. Musher D.M. Streptococcus pneumoniae. Principles and practice of infectious diseases 2010, 2623-2642. Churchill Livingstone, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
33. O'Brien K.L., Hochman M., Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 2007, 7(9):597-606.
34. Hammitt L.L., Bulkow L.R., Singleton R.J., et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011, 29(12):2287-2295.
35. Torling J., Hedlund J., Konradsen H.B., et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22(1):96-103.
36. Rodriguez-Barradas M.C., Groover J.E., Lacke C.E., et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996, 173(6):1347-1353.
37. Black S.B., Shinefield H.R., Ling S., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9):810-815.
38. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
39. Kayhty H., Auranen K., Nohynek H., et al. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 2006, 5(5):651-667.
40. Hammitt L.L., Bruden D.L., Butler J.C., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006, 193(11):1487-1494.
41. Dagan R, Patterson S, Juergens C, et al. The efficacy of the 13-valent conjugate pneumococcal polysaccharide vaccine (PCV13) additional serotypes on nasopharyngeal colonization; a randomized double-blind pediatric trial. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguazu Falls (Brazil), 2012. Abstract #58.
42. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis 2011, 52(5):633-640.
43. Jackson L.A., Neuzil K.M., Nahm M.H., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007, 25(20):4029-4037.
44. de Roux A., Schmole-Thoma B., Siber G.R., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46(7):1015-1023.
45. French N., Gordon S.B., Mwalukomo T., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362(9):812-822.
46. French N., Nakiyingi J., Carpenter L.M., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355(9221):2106-2111.
47. Clutterbuck E.A., Lazarus R., Yu L.M., et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012, 205:1408-1416.
48. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly 2012, 61(40):816-819.
49. Smith K.J., Wateska A.R., Nowalk M.P., et al. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012, 307:804-812.
50. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011, 23(3):407-413.
51. Denoel P., Philipp M.T., Doyle L., et al. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011, 29(33):5495-5501.
52. Salha D., Szeto J., Myers L., et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun 2012, 80(6):2212-2220.